OBJECTIVE: To investigate the effects of continuous i.v. infusion of hydrocortisone or insulin on leptin secretion in humans. SUBJECTS: Six, nonfasting healthy adults (four women, two men), aged (mean AE s.e.m.) 36.6 AE 1.7 y; body mass index (BMI) 27.6 AE 0.9 kgam 2 . DESIGN: Randomized, placebo-controlled, cross-over study, with a 2-week`wash-out' period. INTERVENTIONS: Intravenous infusion of hydrocortisone (3.3 m mga(kg min)), insulin (1 mUa(kg min)) or normal saline (placebo) for 24 h. MEASUREMENTS: Blood sampling every 1 ± 2 h for measurement of glucose, insulin, cortisol and leptin; subcutaneous abdominal fat biopsy for determination of leptin mRNA expression. RESULTS: Plasma cortisol increased to 50.0 AE 0.4 m mgadl during hydrocortisone infusion, but was unaltered during saline or insulin infusion. The plasma insulin levels were: 28.5 AE 4.7 m mUaml (placebo), 40.8 AE 9.2 m mUaml (hydrocortisone, P 0.214), and 243 AE 23.0 m mUaml (insulin, P 0.0002). Peak hyperleptinemia occurred after 16 h of insulin and 20 h of hydrocortisone infusion; peakabaseline plasma leptin levels (ngaml) were 18.2 AE 4.2a15.1 AE 3.3 (placebo, P 0.056), 42.1 AE 7.0a16.0 AE 3.8 (hydrocortisone, 163%, P 0.008) and 30.2 AE 4.3a16.6 AE 2.7 (insulin, 83%, P 0.024). Adipocyte leptin mRNA increased by 350% after the hydrocortisone infusion. CONCLUSION: Hydrocortisone, a natural glucocorticoid, induces hyperleptinemia in vivo, with a potency greater than that of insulin. The interaction between glucocorticoids and leptin may be of metabolic signi®cance in humans.
Introduction
Leptin, a 16 kDa polypeptide hormone, exerts potent effects on appetite, weight regulation and glucose metabolism in rodents. 1 ± 4 The rare reports of congenital leptin de®ciency associated with morbid obesity, hypogonadism and pituitary dysfunction 5, 6 suggest that leptin may have important effects in humans also. However, the hormonal and metabolic factors that regulate human leptin production are incompletely understood. 7 Plasma leptin levels increase by $ 50% following several hours of insulin infusion 8 ± 10 and by $ 100% within 24 ± 48 h of dexamethasone treatment. 11, 12 Glucocorticoids stimulate appetite, increase body weight and induce insulin resistance. 13, 14 The orexogenic effect of glucocorticoids is mediated, at least in part, by augmentation of the hypothalamic feeding signal neuropeptide Y (NPY), 15 an effect that is inhibited by leptin 16, 17 and insulin. 15 Because leptin inhibits food intake and increases insulin sensitivity, 2 ± 4 we hypothesized 12 that hyperleptinemia is a physiological (`counterregulatory') mechanism that probably serves to limit the hyperphagia, weight gain and insulin resistance associated with glucocorticoid therapy. In that case, induction of hyperleptinemia should be a property common to all glucocorticoids.
Surprisingly, synthetic glucocorticoids appear to have discordant effects on leptin: oral dexamethasone 11, 12, 18 increases plasma leptin in a dose-related manner 12 whereas leptin levels were unaltered by methylprednisolone administered i.v. or orally. 19 To further explore this subject, we determined the effect of the natural glucocorticoid hydrocortisone on circulating leptin levels and leptin mRNA abundance in human adipose tissue. We also compared the kinetics of the leptinemic responses to prolonged infusion of insulin or hydrocortisone, using a randomized, crossover, placebo-controlled study design.
27.6 AE 0.9 kgam 2 ) were admitted to the Washington University General Clinical Research Center (GCRC) at 06:00 on day 1 after an overnight fast (no food after 22:00) and discharged after 08:00 the following day. An i.v. cannula was placed in an antecubital vein for infusion of placebo and active agents. Another cannula was placed in a dorsal vein of the contralateral hand, which was warmed in a hot box, to facilitate arterialized blood sampling. Cannulas were placed between 06:00 and 07:00; placebo and active infusions were started at 08:00 and continued for 24 h. Blood sampling was performed 1 h before infusions (À1 h), at the start of infusions (0 h), hourly for 6 h, and every 2 h for the remainder of the 24 h. The subjects ordered their choice of meals from a standard hospital menu; breakfast was served between 08:00 and 09:00, lunch between 12:30 and 13:30, and dinner between 18:00 and 19:00. The food trays were checked by a research dietitian at the beginning and end of each meal. Any snacks consumed between meal times were also recorded. Estimation of protein, fat, carbohydrate and caloric consumption was performed using a Recipe Nutrient Analysis Program (Computrition Inc., Chatsworth, CA). The mean total caloric consumption was 2660 AE 316 kcaladay during placebo and 2166 AE 274 kcaladay during hydrocortisone infusion. The approximate distribution of total calories consumed was 54% carbohydrate, 28% fat and 18% protein. The total caloric consumption during the insulin infusion arm could not be reliably estimated because, in addition to meals, a continuous infusion of dextrose (10%) was administered, to prevent hypoglycemia. None of the subjects was enrolled in a weight loss program and none was taking any medication known to affect leptin levels. All subjects gave their written informed consent for participation in this study, which was approved by the Washington University Medical Center Human Studies Committee.
Infusions and glucose clamp
All six subjects received normal saline (placebo) or hydrocortisone (3.3 mga(kg min)) infusion, on two occasions, in random fashion. Four of the subjects (three women, one man; age 34.8AE 5.9; BMI 28.3 AE 2.3) were studied on a third occasion using insulin infusion (1 mUa(kg min)). Arterialized plasma glucose was measured every 10 min during the insulin infusion, and a variable rate infusion of dextrose (10%) was given to prevent hypoglycemia and maintain a target plasma glucose level of $ 140 mgadl. This target was chosen to create approximately similar glycemic pro®les during the hydrocortisone and insulin arms of the study. To maintain masking of subjects to speci®c interventions, a sham dextrose infusion was orchestrated on the placebo and hydrocortisone intervention days. The studies were separated by a`washout' period of 2 weeks.
Fat biopsy
Subcutaneous adipose tissue specimens were obtained by needle biopsy from a paramedian abdominal region between 07:00 and 08:00 on day 1 before hydrocortisone infusion, and from the contralateral side on day 2, after the intervention. The biopsies were performed under local anesthesia and the specimens were immediately frozen in liquid nitrogen and stored at À70 C.
Analytic methods
Plasma glucose was measured with a glucose oxidase method (Glucose Analyzer 2, Beckman Instruments, Fullerton, CA, USA). Plasma levels of insulin, 20 leptin (Linco Research, St Charles, MO, USA) and cortisol 21 were measured with speci®c radioimmunoassays. The leptin radioimmunoassay detects immunoreactive human leptin with a sensitivity (lowest detectable limit) of 0.5 ngaml in plasma; the intraassay and interassay variation coef®cients were less than 8%. 22 Northern blot analysis Total RNA was extracted from fat biopsy specimens (0.3 g) using a commercial solid-phase spin column procedure (RNeasy; Qiagen Inc., Santa Clarita, CA), air-dried, and the pellet dissolved in 10 ml of DEPC-water. The RNA (10 ml; $ 1.3 mg) was loaded on agarose gel (1%) containing 100 mg ethidium bromide, 1ÂMOPS buffer, and 2.2 M formaldehyde. The gel was run at 60 V for 3 h and the electrophoretic products transferred to a positively charged nylon membrane, which was pre-wetted with 2ÂSSC at 65 C for 15 min and prehybridized with 10 mla100 cm 2 Engle Hybe solution for 1 h. The DIG-labeled leptin cDNA probe (20 ml) was then added, and hybridization was carried out overnight at 65 C. After three 15-min washes with Engler wash
Leptin regulation by insulin and glucocorticoid H Askari et al buffer, the membrane was equilibrated with 10 ml detection wash buffer at room temperature. The membrane was then blocked with 10 ml blocking buffer (detection washing buffer containing 0.5% BM blocking reagent) for 1 h at room temperature. Fresh blocking buffer (5 ml) containing 1:10,000 diluted anti-DIG Fab fragment (Boehringer Mannheim) was added, and the incubation continued for 30 min at room temperature. Posthybridization washes and immunological detection with the DIG-labeled probe were conducted according to Trayhurn et al, 23 
Statistical analysis
The data are expressed as mean AE s.e. The differences in mean 24 h plasma levels of leptin and other analytes during placebo and active infusions were analyzed using paired t-tests. Serial plasma levels of leptin, insulin, cortisol and glucose were analyzed using repeated measures ANOVA with Dunnett's test to con®rm speci®c differences. Statistical analyses were run on an IBM Stat View program (SAS Institute Inc., Cary, NC). P`0.05 was accepted as signi®cant.
Results

Glucose
Fasting plasma glucose levels measured 1 h before infusion of placebo, hydrocortisone and insulin were 95.3AE 4.5, 90.5 AE 1.8 and 89.7AE 5.9 mgadl, respectively. The mean 24 h plasma glucose levels were lower (P 0.01) during placebo infusion (106AE 7.1 mgadl) than during hydrocortisone (143AE 18.5 mgadl) or insulin-glucose (144 AE 4.4 mgadl) infusion (Figure 1) . Transient, postprandial increases ( 30 mgadl) in plasma glucose levels were observed during placebo and active infusions (Figure 1 ).
Cortisol
Plasma cortisol levels were similar during infusion of placebo or insulin, but increased rapidly, and peaked within 1 h, during hydrocortisone infusion (Figure 1 ). The mean 24 h plasma cortisol levels were 8.4 AE 0.9, 11.9 AE 1.2 and 48.0AE 2.4 mgadl (P`0.0001) during placebo, insulin and hydrocortisone infusion, respectively.
Insulin
Compared with placebo, plasma insulin levels were modestly elevated during hydrocortisone infusion and markedly so during insulin infusion (Figure 2 ). The mean 24 h plasma insulin levels during the infusions were 28.5AE 4.7 mUaml (placebo), 40.8AE 9.2 mUaml (hydrocortisone, P 0.214), and 243AE 23 mUaml (insulin, P 0.0002). Transient meal-related increases in plasma insulin levels were noted during the placebo and hydrocortisone arms of the study (Figure 2 ).
Leptin
Plasma leptin levels were similar at baseline and during the initial 5 h following infusion of placebo or active agents (Figure 2) . During saline infusion, plasma leptin levels showed a nocturnal rise 24 that was ®rst observed after 12 h (clock time 20:00) and peaked after 16 h (00:00). The mean baseline (08:00) plasma leptin level was 15.1AE 3.3 ngaml and the peak level (22:00), was 18.2AE 4.2 ngaml (P 0.056). 
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Compared with placebo, signi®cant increases in plasma leptin levels occurred after 6 h of insulin infusion (P 0.048) and 8 h of hydrocortisone infusion (P 0.032). With continued infusions, the plasma leptin increased from 16.0 AE 3.8 ngaml to a peak of 42.1AE 7.0 ngaml (P 0.008) after 20 h of hydrocortisone infusion, and from 16.6AE 2.7 ngaml to a peak of 30.3AE 4.3 ngaml after 16 h (P 0.024) of insulin infusion (Figure 2 ). The mean change in plasma leptin (peak minus baseline), expressed as a percentage of baseline leptin levels, was 83 AE 12% during insulin infusion and 163 AE 28% during hydrocortisone infusion. Compared with insulin, hydrocortisone infusion resulted in a greater (P 0.02) percentage rise in plasma leptin. Once attained, peak leptin levels were sustained throughout the duration of insulin infusion, but tended to decline after the twentieth hour during hydrocortisone infusion. No acute postprandial changes in plasma leptin levels were evident during infusion of placebo, insulin or hydrocortisone (Figure 2 ). Figure 3 shows the results of Northern blot analysis of leptin mRNA levels in subcutaneous fat biopsy specimens from two representative subjects (one male and one female). The leptin mRNA abundance (expressed as a ratio of b-actin abundance,AE s.d.) was unchanged after the 24 h saline infusion, but increased approximately 3-fold after the 24 h hydrocortisone infusion.
Discussion
The results of the present study show that continuous infusion of hydrocortisone, a natural glucocorticoid, results in increased plasma leptin levels in humans, after a lag time of $ 8 h. The plasma leptin response to hydrocortisone was associated with increased leptin mRNA abundance in adipose tissue following the 24 h hydrocortisone infusion. Our data are in accord with previous reports that showed up to $ 100% increase in plasma leptin levels 11, 12, 18 and adipose tissue leptin mRNA levels 18 24 ± 48 h following oral administration of dexamethasone. Furthermore, by utilizing an intravenous study design, we obtained new information on the time course of, and adaptation to, Leptin regulation by insulin and glucocorticoid H Askari et al hyperleptinemia during glucocorticoid stimulation. The plasma leptin response to continuous hydrocortisone infusion was observed after a lag time of $ 8 h and was maximal by 20 h. After 20 h, plasma leptin levels tended to decline (despite continuing glucocorticoid infusion), suggesting that there might be an adaptive mechanism acting against sustained glucocorticoid activation of adipocyte leptin output. In a recent report, a signi®cant increase in serum leptin occurred 7 h following an i.v. bolus of dexamethasone (4 mg) in fed subjects; interestingly, fasting markedly attenuated the leptin response. 25 Our data con®rm that stimulation of leptin production is not restricted to dexamethasone, a type II glucocorticoid receptor-speci®c ligand, but also occurs with hydrocortisone, a natural ligand for both type I and type II glucocorticoid receptors. 26 Based on reports that leptin inhibits glucocorticoid secretion 27 and dexamethasone stimulates leptin secretion, 11, 12, 18, 25 an interregulatory feedback loop between leptin and glucocorticoids has been postulated. 7, 12 Such an interaction may represent an important mechanism for modulating glucocorticoid availability and ingestive behavior under various metabolic and stressful conditions. Thus the present study, by showing that a natural glucocorticoid induces hyperleptinemia, strengthens the possible metabolic relevance of glucocorticoid ± leptin interaction in humans.
Because glucocorticoids induce insulin resistance and hyperinsulinemia, 28 it can be argued that their effect on plasma leptin is mediated by the hyperinsulinemia. 8 ± 10 To address this issue, we compared ambient insulin and leptin levels during infusion of insulin or hydrocortisone. Compared with hydrocortisone, signi®cant hyperleptinemia occurred 2 h earlier and peaked 4 h earlier during insulin infusion. Although plasma insulin levels were 6-fold higher during insulin infusion, the increase in plasma leptin during hydrocortisone infusion was 2-fold higher than that observed during insulin infusion.
The plasma leptin response to insulin is doserelated. 10 In healthy, fasting subjects receiving a 9 h insulin infusion under clamped euglycemic conditions, plasma insulin levels of 34 mUaml (204 pmolal), 64 mUaml (384 pmolal), 132 mUaml (792 pmolal), and 1725 mUaml (10,350 pmolal) were associated with maximum increases in plasma leptin levels of`5%, 20%, 30% and 60% above baseline, respectively. 10 The increase in plasma leptin among our patients (with a mean plasma insulin level of 243 mUaml) was 33% after 9 h, similar to that seen at a comparable dose and time point in the dose ± response study of Saad et al. 10 In contrast, plasma leptin levels were much higher than would have been predicted from ambient insulinemia during the hydrocortisone infusion. Nonetheless, hyperinsulinemia (induced by feeding or glucocorticoid) must play a permissive role in glucocorticoid-induced hyperleptinemia, in light of the recent report that fasting blunts the leptin response to dexamethasone. 25 Plasma leptin levels reportedly were unaltered by methylprednisolone administered i.v. (125 mg bolus) and orally (40 mgaday for 4 days) in healthy subjects. 18 The reason for this discordant report is unclear, especially since another analogue, prednisolone (25 mg twice daily, orally, for 4 days), has been demonstrated to increase human plasma leptin levels signi®cantly. 29 Moreover, we have recently shown that a single (nearphysiological) dose of hydrocortisone (40 mg) signi®-cantly increases plasma leptin. 30 In conclusion, the natural glucocorticoid, hydrocortisone, increases leptin mRNA expression in human adipose tissue, and increases plasma leptin levels in healthy subjects. The metabolic signi®cance of the interaction between glucocorticoids and leptin remains to be elucidated.
